PMC:7799377 / 831-1424 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":102,"end":222},"obj":"Sentence"},{"id":"T14","span":{"begin":223,"end":435},"obj":"Sentence"},{"id":"T15","span":{"begin":436,"end":579},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ological consequences although respiratory symptoms nearly always develop prior to neurological ones. Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms. Neurological reports in COVID-19 patients have described encephalopathy, Guillain-Barré syndrome, myopathy, neuromuscular disorders, encephalitis, cephalgia, delirium, critical illness polyneuropathy, and others. Treating neurological symptoms can pose clinical challenges as drugs that suppress immune response may be contraindicated in COVID-19 patients. It is possibl"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":280,"end":294},"obj":"Phenotype"},{"id":"T2","span":{"begin":321,"end":329},"obj":"Phenotype"},{"id":"T3","span":{"begin":356,"end":368},"obj":"Phenotype"},{"id":"T4","span":{"begin":381,"end":389},"obj":"Phenotype"},{"id":"T5","span":{"begin":408,"end":422},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001298"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0003198"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002383"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0031258"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001271"}],"text":"ological consequences although respiratory symptoms nearly always develop prior to neurological ones. Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms. Neurological reports in COVID-19 patients have described encephalopathy, Guillain-Barré syndrome, myopathy, neuromuscular disorders, encephalitis, cephalgia, delirium, critical illness polyneuropathy, and others. Treating neurological symptoms can pose clinical challenges as drugs that suppress immune response may be contraindicated in COVID-19 patients. It is possibl"}

{"project":"LitCovid-PubTator","denotations":[{"id":"38","span":{"begin":102,"end":110},"obj":"Species"},{"id":"39","span":{"begin":256,"end":264},"obj":"Species"},{"id":"40","span":{"begin":570,"end":578},"obj":"Species"},{"id":"50","span":{"begin":31,"end":51},"obj":"Disease"},{"id":"51","span":{"begin":180,"end":188},"obj":"Disease"},{"id":"52","span":{"begin":200,"end":221},"obj":"Disease"},{"id":"53","span":{"begin":247,"end":255},"obj":"Disease"},{"id":"54","span":{"begin":280,"end":294},"obj":"Disease"},{"id":"55","span":{"begin":321,"end":329},"obj":"Disease"},{"id":"56","span":{"begin":331,"end":354},"obj":"Disease"},{"id":"57","span":{"begin":356,"end":368},"obj":"Disease"},{"id":"58","span":{"begin":370,"end":379},"obj":"Disease"},{"id":"59","span":{"begin":381,"end":389},"obj":"Disease"},{"id":"60","span":{"begin":391,"end":422},"obj":"Disease"},{"id":"61","span":{"begin":445,"end":466},"obj":"Disease"},{"id":"62","span":{"begin":561,"end":569},"obj":"Disease"}],"attributes":[{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:9606"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:9606"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D012818"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:C000657245"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D009422"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:C000657245"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D001927"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D009135"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D009468"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D004660"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D006261"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D003693"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D011115"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D009422"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ological consequences although respiratory symptoms nearly always develop prior to neurological ones. Patients with preexisting neurological conditions may be at elevated risk for COVID-19-associated neurological symptoms. Neurological reports in COVID-19 patients have described encephalopathy, Guillain-Barré syndrome, myopathy, neuromuscular disorders, encephalitis, cephalgia, delirium, critical illness polyneuropathy, and others. Treating neurological symptoms can pose clinical challenges as drugs that suppress immune response may be contraindicated in COVID-19 patients. It is possibl"}